Literature DB >> 12438519

Nonpeptide factor Xa inhibitors III: effects of DPC423, an orally-active pyrazole antithrombotic agent, on arterial thrombosis in rabbits.

Pancras C Wong1, Earl J Crain, Carol A Watson, Alverna M Zaspel, Matthew R Wright, Patrick Y Lam, Donald J P Pinto, Ruth R Wexler, Robert M Knabb.   

Abstract

DPC423 [1-[3-(aminomethyl)phenyl]-N-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide] is a synthetic, competitive, and selective inhibitor of coagulation factor Xa (fXa) (K(i): 0.15 nM in humans, 0.3 nM in rabbit). The objective of this study was to compare effects of DPC423, enoxaparin (low-molecular-weight heparin), and argatroban (thrombin inhibitor) on arterial thrombosis and hemostasis in rabbit models of electrically induced carotid artery thrombosis and cuticle bleeding, respectively. Compounds were infused i.v. continuously from 60 min before artery injury or cuticle transection to the end of experiment. Carotid blood flow was used as a marker of antithrombotic effect. Antithrombotic ED(50) values were 0.4 mg/kg/h for enoxaparin (n = 6), 0.13 mg/kg/h for argatroban (n = 6), and 0.6 mg/kg/h for DPC423 (n = 12). DPC423 at the maximum antithrombotic dose increased activated partial thromboplastin time and prothrombin time (n = 6) by 1.8 +/- 0.07- and 1.8 +/- 0.13-fold, respectively, without changes in thrombin time and ex vivo thrombin activity. The antithrombotic effect of DPC423 was significantly correlated with its ex vivo anti-fXa activity (r = 0.86). DPC423 at 1, 3, and 10 mg/kg p.o. increased carotid blood flow (percent control) at 45 min to 10 +/- 4, 24 +/- 6, and 74 +/- 7, respectively (n = 6/group). Cuticle bleeding times (percent change over control) determined at the maximum antithrombotic dose were 88 +/- 12 for argatroban, 69 +/- 13 for heparin, 4 +/- 3 for enoxaparin, 5 +/- 4 for DPC423, and -3 +/- 2 for the vehicle (n = 5-6/group), suggesting dissociation of antithrombotic and bleeding time effects for DPC423 and enoxaparin. The combination of aspirin and DPC423 at ineffective antithrombotic doses produced significant antithrombotic effect. Therefore, these results suggest that DPC423 is a clinically useful oral anticoagulant for the prevention of arterial thrombosis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12438519     DOI: 10.1124/jpet.102.040089

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

1.  Discovery of a Potent Parenterally Administered Factor XIa Inhibitor with Hydroxyquinolin-2(1H)-one as the P2' Moiety.

Authors:  Zilun Hu; Pancras C Wong; Paul J Gilligan; Wei Han; Kumar B Pabbisetty; Jeffrey M Bozarth; Earl J Crain; Timothy Harper; Joseph M Luettgen; Joseph E Myers; Vidhyashankar Ramamurthy; Karen A Rossi; Steven Sheriff; Carol A Watson; Anzi Wei; Joanna J Zheng; Dietmar A Seiffert; Ruth R Wexler; Mimi L Quan
Journal:  ACS Med Chem Lett       Date:  2015-04-08       Impact factor: 4.345

2.  Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor.

Authors:  Kan He; Joseph M Luettgen; Donglu Zhang; Bing He; James E Grace; Baomin Xin; Donald J P Pinto; Pancras C Wong; Robert M Knabb; Patrick Y S Lam; Ruth R Wexler; Scott J Grossman
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2011-04-02       Impact factor: 2.441

3.  In vitro, antithrombotic and bleeding time studies of BMS-654457, a small-molecule, reversible and direct inhibitor of factor XIa.

Authors:  Pancras C Wong; Mimi L Quan; Carol A Watson; Earl J Crain; Mark R Harpel; Alan R Rendina; Joseph M Luettgen; Ruth R Wexler; William A Schumacher; Dietmar A Seiffert
Journal:  J Thromb Thrombolysis       Date:  2015-11       Impact factor: 2.300

Review 4.  Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor.

Authors:  Pancras C Wong; Donald J P Pinto; Donglu Zhang
Journal:  J Thromb Thrombolysis       Date:  2011-05       Impact factor: 2.300

5.  Tissue factor, blood coagulation, and beyond: an overview.

Authors:  Arthur J Chu
Journal:  Int J Inflam       Date:  2011-09-20

6.  Razaxaban, a direct factor Xa inhibitor, in combination with aspirin and/or clopidogrel improves low-dose antithrombotic activity without enhancing bleeding liability in rabbits.

Authors:  Pancras C Wong; Earl J Crain; Carol A Watson; Ruth R Wexler; Patrick Y S Lam; Mimi L Quan; Robert M Knabb
Journal:  J Thromb Thrombolysis       Date:  2007-02-24       Impact factor: 5.221

Review 7.  Development of apixaban: a novel anticoagulant for prevention of stroke in patients with atrial fibrillation.

Authors:  Michael S Hanna; Puneet Mohan; Robert Knabb; Elora Gupta; Charles Frost; John H Lawrence
Journal:  Ann N Y Acad Sci       Date:  2014-11-05       Impact factor: 5.691

8.  From basic science to life-saving therapy: the rationale, and drug discovery efforts that led to the direct factor Xa inhibitor eliquis.

Authors:  Robert M Knabb; Ruth R Wexler
Journal:  J Thromb Thrombolysis       Date:  2021-08-05       Impact factor: 2.300

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.